Event organizer will implement charitable giving through non-profit’s vaccine donation program.
Pharmaceutical Business Conference Group (PBCG), a clinical trials conference organizer, will partner with Greater Gift, a non-profit with the mission to increase awareness of clinical research as a care option, to implement charitable giving programs at its Clinical Outsourcing Group meetings, which are held globally throughout the year.
"We are thrilled to partner with Pharmaceutical Business Conference Group to further our mission and simplify the process for corporations and individuals to contribute to pay forward the gift of health," said Joan Chambers, CEO of Greater Gift, in a release. She added, "PBCG events attract top leaders in the pharmaceutical space, establishing their conferences as an ideal platform for increasing charitable contributions from this community."
The program will utilize Greater Gift’s collaboration with GAVI, the Vaccine Alliance. PBCG outsourcing speakers will use a referral code for pharmaceutical and biotech colleagues to register, triggering a PBCG donation. The charity, with GAVI, then donates a vaccine to a child in need. Registrants receive notification post-event as to how many donations their contributions made.
The new charitable referral program debuts at PBCG's Clinical Outsourcing Group Europe meeting on October 10 and 11 in Milan, Italy.
Reference: “Pharmaceutical Business Conference Group Partners with Greater Gift to Expand Vaccine Donation Programme,”London, United Kingdom, August 23, 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.